Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 8345 - 8352 of 12089 results
Hospitals Settle DOJ Suit Alleging Illegal Division of Marketing Territories
April 18, 2016| Blog| Viewpoint
Immigration Policy By Lottery? Another Year, Nothing Changes.
April 18, 2016| Blog| Viewpoint
Key Lessons from Patent Litigation for Drafting and Prosecuting Utility Patent Applications
April 15, 2016| Blog| Viewpoint
Data Center Development and Financing Strategies (AreaDevelopment)
April 15, 2016| Blog| Viewpoint
Zen Magnets Claims “90% Victory” Against CPSC in Magnet Recall Litigation
April 15, 2016| Blog| Viewpoint
Mintz's Health Care Enforcement Defense Group Publishes New Qui Tam Update
April 14, 2016| Blog| Viewpoint
Article 29 Working Party Opinions on Privacy Shield and Surveillance
April 14, 2016| Blog| Viewpoint
A Decade Later, Rules for the Sanitary Transportation of Food Finally Finalized by FDA
April 14, 2016| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|